
Crossover to bezuclastinib plus sunitinib after progression on sunitinib improved PFS and responses in GIST in phase 3 PEAK, with no new safety signals.
Evolving Paradigms
This section covers the Current Treatment Strategies section of the current Evolving Paradigms in Soft Tissue Sarcoma issue.
Currently, STS is difficult to treat due to its heterogeneity and the lack of available treatments. With advances in the knowledge of genetics, understanding of STS continues to increase. This increase of knowl- edge has promoted, and will continue to promote, the development of targeted therapies, which may aid in personalizing treatment and will help shape future standards of care.
almost 10 years ago
Evolving Paradigms in Soft Tissue Sarcoma: Current and Emerging Targetsalmost 10 years ago
Evolving Paradigms in Soft Tissue Sarcoma: Current Treatment Strategiesalmost 10 years ago
Evolving Paradigms in Soft Tissue Sarcoma: Introduction